Opinion: STAT+: Promising signs for stem cell-based therapies for Parkinson’s in two new studies
Cell therapy development for Parkinson’s disease has been a marathon. Two new papers represent an important step forward.
Welcome to Lab Dish, a new First Opinion column on regenerative medicine from Paul Knoepfler.
I’m upbeat about cell therapy development for Parkinson’s disease, but it has been a marathon. Now two new clinical trial papers published Wednesday in Nature on stem cell-based therapies for Parkinson’s are another step forward.
However, they also highlight remaining challenges and dilemmas, including the optimal doses of cells, the extent of engraftment, and whether to use allogeneic or autologous cells.
